%0 Journal Article
%T Clinical and molecular characterization of myotonia congenita using whole-exome sequencing in Egyptian patients.
%A Elaraby NM
%A Ahmed HA
%A Dawoud H
%A Ashaat NA
%A Azmy A
%A Galal ER
%A Elhusseny Y
%A Awady HE
%A Metwally AM
%A Ashaat EA
%J Mol Biol Rep
%V 51
%N 1
%D 2024 Jun 15
%M 38877370
%F 2.742
%R 10.1007/s11033-024-09646-8
%X <B>BACKGROUND: </B>Myotonia Congenita (MC) is a rare disease classified into two major forms; Thomsen and Becker disease caused by mutations in the CLCN1 gene, which affects muscle excitability and encodes voltage-gated chloride channels (CLC-1). While, there are no data regarding the clinical and molecular characterization of myotonia in Egyptian patients.<BR><B>METHODS: </B>Herein, we report seven Egyptian MC patients from six unrelated families. Following the clinical diagnosis, whole-exome sequencing (WES) was performed for genetic diagnosis. Various in silico prediction tools were utilized to interpret variant pathogenicity. The candidate variants were then validated using Sanger sequencing technique.<BR><B>RESULTS: </B>In total, seven cases were recruited. The ages at the examination were ranged from eight months to nineteen years. Clinical manifestations included warm-up phenomenon, hand grip, and percussion myotonia. Electromyography was performed in all patients and revealed myotonic discharges. Molecular genetic analysis revealed five different variants. Of them, we identified two novel variants in the CLCN1 gene ( c.1583G > C; p.Gly528Ala and c.2203_2216del;p.Thr735ValfsTer57) and three known variants in the CLCN1 and SCN4A gene. According to in silico tools, the identified novel variants were predicted to have deleterious effects.<BR><B>CONCLUSIONS: </B>As the first study to apply WES among Egyptian MC patients, our findings reported two novel heterozygous variants that expand the CLCN1 mutational spectrum for MC diagnosis. These results further confirm that genetic testing is essential for early diagnosis of MC, which affects follow-up treatment and prognostic assessment in clinical practice.